Appendix G — Regulatory and Legal Quick Reference

Chapter 38 makes an argument. This appendix is looked things up in.

That difference governs how the page is built. This appendix assumes you already accept Chapter 38's argument. It exists for the moment three months from now when you hit the word biosimilar, or 503B, or S0, half-recall what it means, and want the other half in under a minute. So: short entries, scannable headings, tables wherever a table beats a paragraph, and a glossary at §G.10.

One thing travels with the facts and cannot be separated from them — repeated here because a reference page is exactly where it gets lost:

Regulatory status is not evidence — in either direction. Approval tells you what was submitted and how it was judged. Non-approval, most of the time, tells you that nobody submitted anything. Neither tells you what is known about the molecule. That is Chapter 38 §38.10, and every entry below is written to be usable without violating it.

If you use a fact from this appendix to move an evidence rating up or down, you have misused the appendix. These facts are for reading claims, not for rating compounds.

G.1 The standing caveat — read this before using any other section

⚠️ This is not legal advice.

It is not a description of the law where you live. Regulatory rules differ enormously between countries — and often within them — and they change. Sometimes annually, sometimes in the middle of litigation, sometimes because an agency published a document on a Tuesday.

Nothing here tells you what you may lawfully do, buy, possess, or carry. That is not an oversight. The answer differs by jurisdiction, changes without notice, and is not something a general-audience textbook can responsibly assert about your situation.

Everything is date-stamped: as of this writing, in 2026. If you are reading this well after that, assume the specifics have moved and the reasoning has not.

If you have an actual question, the answer is not in a book. It is in the current rules of your own jurisdiction, read by someone qualified to interpret them.

Scope

This page is oriented mainly toward United States structures, for a reason that is linguistic as much as legal: the vocabulary most readers meet — "FDA approved," "503B," "research use only," "it's a supplement" — originates in the United States system and is then applied, often incorrectly, to products and readers elsewhere. To read those phrases you have to know what they mean where they came from.

Where another system differs in a way that matters to reading a claim, this appendix says so. It does not pretend to cover other systems; doing that properly would take a book per jurisdiction. §G.11 offers a way of thinking about other jurisdictions instead, which is the durable thing.

What is deliberately absent

There is no section on personal importation, possession, or carrying anything across a border. Chapter 38 §38.9 declined that topic and this appendix declines it for the same reasons: those rules differ enormously between countries and within them, and they change. This book does not advise on them. If that is your question, it belongs with someone qualified in your own jurisdiction, and no sentence anywhere in this appendix should be read as an answer to it.

G.2 What "approved" means, in one screen

A compact restatement of Chapter 38 §38.1.

An approval is a regulator's judgment that, for a specified indication and population, the evidence submitted shows the benefits outweigh the risks — together with an approved label describing that use, the population studied, the dosing evaluated, the adverse events observed, and the warnings the agency considers necessary.

Four qualifiers do all the work.

What approval is not, in four negatives, each one a claim somebody has actually made. It is not a statement that the drug works for everyone in the approved population; trials report averages and distributions. Not a statement that all long-term effects are known; they are known to the extent they were studied, over the horizon studied. Not a statement that the drug beats the alternatives; many approvals rest on placebo-controlled trials. And not permanent — drugs are withdrawn, labels revised, boxed warnings added, indications removed.

The correct formulation, from Chapter 38 §38.10: approval is strong evidence about a narrow claim. Strong, because a regulator with the full dataset — including analyses that never reach the literature — read it and was persuaded. Narrow, because it is bounded by indication, population, and endpoint. Drop "strong" and you become the cynic who thinks approvals mean nothing. Drop "narrow" and you read a label as a certificate.

⚠️ Not legal advice. United States framing as of this writing in 2026; other systems use different terms for a broadly similar judgment (§G.11). Rules differ by jurisdiction and change.

G.3 The forty-amino-acid line

The most concrete regulatory fact in this book, and it is a number.

In the United States, as of this writing in 2026: an alpha-amino-acid polymer with a specific, defined sequence of more than 40 amino acids is regulated as a biological product. Forty or fewer, and it is regulated as a drug.

Nothing chemical happens at residue 41. Chapter 1 made the same observation about the peptide/protein naming convention, with one difference: here the arbitrary line has legal force.

Why the pathways are not equivalent. A generic application does not repeat the clinical program: demonstrate bioequivalence, and the agency accepts that the original efficacy data applies. A biosimilar cannot work that way, because a large biological molecule made in living cells is not reproducible atom for atom by a second manufacturer using a different cell line and process. That pathway therefore asks for extensive analytical characterization, usually pharmacokinetic and immunogenicity work, often a comparative clinical study — and then, for pharmacy-level substitution, a further interchangeability determination. Abbreviated relative to an original application; still far slower and more expensive than a generic filing.

Insulin crossed the line

The cleanest worked case, because it did not stay on one side.

Insulin is 51 amino acids across two chains (Chapter 11) — comfortably over. But it was approved in the United States long before the modern biologics framework existed and was historically regulated as a drug, under NDAs. That legacy produced the worst of both worlds: it sat in the drug system, where the generic pathway theoretically applied but does not actually work for a recombinant protein made in living cells, and it had no access to the biosimilar pathway designed for exactly that kind of molecule.

Under a statutory transition that took effect in March 2020, insulin and a set of other protein products were deemed to be biological products, moving from NDAs into the biologics framework — which is what opened the biosimilar pathway for insulin. Whether the resulting price effects have been large or modest is a separate and live argument; the mechanism is not in dispute.

Now the contrast. Semaglutide's peptide backbone is 31 residues (Chapter 33 covers the modifications hung off it) and tirzepatide is 39 — both on the drug side, the second with two residues to spare. When exclusivity ends, the route open to competitors is the generic route, not the biosimilar route.

Where the count gets slippery

Read the qualifiers: an alpha amino acid polymer (the standard backbone from Chapter 1), with a specific, defined sequence, measured in amino acids — not in daltons. Semaglutide is roughly 4,100 Da and insulin roughly 5,800 Da, not an enormous gap in mass — but semaglutide is 31 residues and insulin is 51, and it is the residue count that decides. A heavily modified peptide can carry a great deal of non-amino-acid mass in fatty acid chains, linkers, and conjugates without moving toward the line at all.

Genuine edge cases exist — chains joined by disulfide bonds, peptides with substantial non-peptide components, molecules where "specific, defined sequence" is arguable — and they get resolved case by case, in resolutions that are exactly the kind of thing that changes. What does not change is the shape of the question: how many alpha amino acids, in a defined sequence, in the polymer?

⚠️ Not legal advice. The forty-amino-acid line is a United States definitional rule as of this writing in 2026; other systems draw the drug/biologic boundary differently or by other criteria. Rules differ by jurisdiction and change.

G.4 The approval pathway, as a diagram and a table

THE DEVELOPMENT PATHWAY        (United States framing, 2026; other agencies structurally similar)

  PRECLINICAL ──▶ IND ──▶ PHASE 1 ──▶ PHASE 2 ──▶ PHASE 3 ──▶ APPLICATION ──▶ PHASE 4 /
                                                                REVIEW        POST-MARKETING
                          │                    ╰──────┬──────╯   (NDA or BLA)
                          │                           │
                          │                    attrition concentrates HERE —
                          │                    where human efficacy is first
                          │                    actually tested
                          │
                    nothing before this point has
                    been given to a human being

The diagram's one editorial claim is the arrow in the middle: compounds are lost at every stage, but the losses concentrate at late Phase 2 and Phase 3 — exactly where the question "does this help a person" first gets a real answer. Everything earlier is, in a precise sense, a prediction. Chapter 10 gives the base rates; the consequence for reading Part III is that a compound with encouraging animal data and no human efficacy trials is not "nearly there," it is sitting immediately before the stage where most encouraging compounds die.

Accelerated pathways. Under defined circumstances — usually serious conditions with unmet need — an agency may approve a drug on the basis of a surrogate endpoint reasonably likely to predict clinical benefit, rather than on the clinical benefit itself, and require confirmatory trials afterward. Connect this straight to Chapter 16, which is about why a surrogate can move convincingly while the outcome patients care about does not. That is not an outside criticism of regulation. It is a designed feature of it. The trade is explicit: confirmation is deferred, not waived, and the system's integrity depends on those trials being run and having consequences when they fail. So "approved on an accelerated pathway" should change how you read an approval — not because the drug does not work, but because it is a different epistemic object from a full approval on a hard clinical endpoint.

One reading rule for the whole pathway: "in clinical trials" is a statement about activity, not about findings. Ask which phase, for what indication. A registered trial is not a result.

⚠️ Not legal advice. Phase names and the IND/NDA/BLA vocabulary are United States terms as of this writing in 2026; other agencies run structurally similar processes under different names. Rules differ by jurisdiction and change.

G.5 "Not FDA approved," five ways

The most useful table in this appendix. The phrase is used as though it means one thing. It means at least five, and the evidential implications are completely different.

Same four words. Five situations. One is a negative finding and four are not.

(1) Never submitted is the situation for the great majority of the compounds in Part III. There is no rejection on file because there is no file. The economics, from Chapter 38 §38.10 and Chapter 36, form a chain in which every link is money rather than biology: no one submitted an application; no one submitted because no one funded the trials; no one funded the trials because there is no patentable commercial position in a well-known short sequence. A competitor could sell the identical molecule the day after approval, so the program never happens. That is a real flaw in how medical evidence gets funded — and it predicts that good and bad compounds alike go unstudied, which is why an empty file carries no information.

(2) Submitted and rejected is the one case where non-approval is itself evidence about the molecule; notice how rarely it is the case actually in front of you. (3) Approved elsewhere — thymosin alpha-1 (Chapter 18) is this book's standing example. (5) Not a drug at all covers three genuinely different regimes, which §G.8 separates.

The discipline, in one worked case

For BPC-157, the answer is case (1): no application submitted for approval as a drug in the United States, no rejection, no adverse regulatory finding on the merits. The file is empty. And Chapter 17's ❌ rating for BPC-157 does not rest on that regulatory status at all. It rests on the published human literature, which is — as of this writing, in 2026 — essentially absent for the claims being made. If a well-designed randomized human trial were published tomorrow showing benefit, the rating would move and the regulatory status would not have changed by one comma.

Two independent facts about one molecule. Holding both without letting either pull on the other is the skill this appendix exists to support.

⚠️ Not legal advice. "FDA approved" is a United States phrase; the same five-way ambiguity applies to equivalent phrasing in other systems, with different agency names. As of this writing in 2026. Rules differ by jurisdiction and change.

G.6 Off-label prescribing

The asymmetry, and it is deliberate:

Why the asymmetry exists. Evidence accumulates in the literature long before — and sometimes instead of — a sponsor assembling it into an application. Whole fields depend on this: substantial portions of pediatric prescribing, of oncology, and of psychiatry involve uses never formally submitted, because the supporting trials were run by academic investigators rather than by companies seeking a label expansion. Restrict prescribing to labeled indications and a great deal of well-supported medicine becomes unavailable for administrative reasons. Meanwhile the burden sits where the profit is: a manufacturer that wants to make a claim must submit the evidence and have it judged. The asymmetry preserves clinical freedom while keeping the evidentiary burden on the party that benefits from the claim.

Off-label is not a synonym for unsupported

This is the part that gets lost. "Off-label" describes a relationship between a use and a label. It describes nothing about the state of the evidence.

• Some off-label uses rest on substantial published evidence — multiple randomized trials, professional-society guidelines, decades of clinical experience — that no sponsor had commercial reason to submit for a label change. Common with older drugs whose exclusivity has expired: there is no return on funding a label expansion for a molecule anyone can now manufacture.
• Some off-label uses rest on very little — a mechanistic argument, a small open-label series, and enthusiasm.

The label is silent on both, identically. So: the label tells you what was submitted and approved; it does not tell you what is known. To find out what is known you do what Chapter 5 taught — population, intervention, comparison, endpoint, effect size, design quality.

This also disposes of a move you will meet in clinics that market peptide services. "It's prescribed by a licensed physician" is a statement about who wrote the prescription, not about evidence. Note also the category confusion often buried in it: prescribing an approved drug off-label is case (4) of §G.5, while obtaining something that is not an approved drug anywhere is a different situation entirely — and both get described to patients in the same reassuring words.

⚠️ Not legal advice. The prescribe/promote asymmetry as described is United States practice, and broadly similar arrangements elsewhere differ in real detail. As of this writing in 2026. Rules differ by jurisdiction and change.

G.7 Compounding: 503A and 503B

A compounding pharmacy prepares a medication for an individual patient — combining, mixing, or altering ingredients to produce something not commercially available in the needed form. The classic cases are genuinely necessary: a patient allergic to a dye in the commercial tablet, a child needing a liquid version of a capsule-only drug. Compounding is old, legitimate, and not manufacturing. The two names below come from sections of United States federal law.

The bottom row is the teaching point, and it is identical on both sides. Compounded drugs are not FDA-approved products, in either category. 503B brings real manufacturing oversight — sterility, quality systems, inspection — a substantial improvement over none. It does not bring a regulator's judgment that the product works, or that its benefits outweigh its risks for a stated indication. The 503B category exists because of a specific failure: a fungal meningitis outbreak traced to contaminated compounded injections made clear that some "compounders" were operating at industrial scale under pharmacy-level oversight.

The shortage mechanism

Ordinarily, compounding a product that is essentially a copy of a commercially available approved drug is restricted — the point of compounding is to serve needs the approved product cannot, not to produce a parallel supply of it. But when a drug appears on the official shortage list, compounding of what would otherwise be an essentially-a-copy product is permitted in defined circumstances, on the reasoning that a patient who cannot obtain the approved drug is not helped by a rule that also blocks the compounded version. And when the shortage is declared resolved, that permission narrows and compounders must wind down.

This is the mechanism behind the largest peptide story of the mid-2020s. During that period, semaglutide and tirzepatide were in shortage in the United States, and a very large compounded market grew up in the window — telehealth prescribing, 503A and 503B supply, extensive consumer marketing. The shortages were subsequently declared resolved during that period, the permission narrowed, and the compounded market faced restriction. The details and the timing were contested, including in litigation, and this book does not adjudicate them. The structure is what matters: a temporary legal permission created a market, and removing the permission removed the market's basis.

A compounded version of a drug is not the approved drug

It may contain the same active molecule. It may not. Even where it does, four differences recur (Chapter 19 develops each): different salt or ester forms, never the subject of the approval; different concentrations, where errors are a documented source of harm that has generated poison-center reports; different delivery devices, since an approved pen is a metering device reviewed alongside the drug while a vial and syringe transfers the metering job to a person at home; and different additives never evaluated with any approved product.

None of that makes every compounded product bad. It makes every compounded product a different product from the approved one, which means the approved product's clinical evidence does not transfer to it automatically — and it is transferred automatically, constantly, in marketing.

⚠️ Not legal advice. 503A and 503B are United States categories, described as of this writing in 2026; other systems handle pharmacy preparation under entirely different frameworks. Whether any particular product may be obtained, by anyone, is not addressed here. Rules differ by jurisdiction and change.

G.8 Supplements, "research chemicals," and cosmetics

Three separate regimes, constantly confused, each doing work in peptide marketing that it cannot actually do.

Dietary supplements

In the United States, the Dietary Supplement Health and Education Act of 1994 (DSHEA) created a category with no premarket approval requirement. A supplement does not have to be shown safe and effective before it is sold; enforcement is largely after the fact. That is the defining feature of the category, not a loophole in it.

But DSHEA did not make the category unlimited: a substance must actually qualify as a dietary ingredient to be sold in it. The definition covers things like vitamins, minerals, herbs and other botanicals, amino acids, and certain substances used in the food supply, plus a notification pathway for new dietary ingredients. A synthetic peptide that has never been part of the food supply and does not fit the statutory categories is not automatically a dietary ingredient because someone put it in a capsule.

Regulators have taken exactly that position for certain peptides — BPC-157 among them. As of this writing in 2026, the United States regulator has taken the position that it does not qualify as a dietary ingredient, and has therefore treated products marketed as supplements containing it as outside the category. Separately, compounds including BPC-157 have been placed on lists identifying bulk substances that present significant safety risks for use in compounding — a different mechanism, aimed at a different channel, pointing the same direction. So, plainly: "sold as a supplement" is not a regulatory endorsement, and for several compounds in this book it is not even a lawful classification.

"Research use only"

Genuine research reagents exist: laboratories need compounds, those compounds are sold, and they are not drugs because they are not offered for administration to human beings. What is not real is the use of that label as a shield on a product obviously configured for human use — priced by the milligram in injectable-friendly vial sizes, marketed alongside reconstitution accessories, and accompanied by a disclaimer nobody involved believes.

"Research use only" is a liability posture, not a regulatory category. No agency conferred it. It is a sentence written by a seller, for the seller's benefit. It does not change what is in the vial, does not change what happens when it enters a person, and confers none of the assurances a real regulatory category would.

Notice what it transfers risk away from: manufacturing standards for human use, a reviewed label, adverse-event reporting obligations, and any mechanism by which a purchaser could learn what happened to other purchasers. Chapter 34 is the empirical follow-up — when independent analyses have looked at what is actually in gray-market vials, the answers have included wrong identity, wrong quantity, and contaminants.

Cosmetics — the best observation in this section

Cosmetic regulation is a third and distinct regime (Chapter 30 owns it), generally without premarket approval, and it carries a constraint that explains something you have probably noticed without being able to name it.

A cosmetic may not lawfully claim to alter the structure or function of the body. A product that makes a therapeutic claim risks being treated as an unapproved drug precisely because it made the claim — the claim, not the ingredient, is what moves a product across the category line.

Now reread cosmetic peptide marketing with that in mind. "Supports the look of firmer skin." "Helps improve the appearance of fine lines." "For a more youthful-looking complexion." The awkward, hedged, appearance-focused phrasing that reads as marketing evasiveness is very often regulatory compliance. The copywriter is not being coy about the evidence; they are staying inside a category boundary, because a sentence claiming the product rebuilds collagen would be a structure-function claim, and a product making it would be inviting classification as an unapproved drug.

Two consequences for reading, pointing in opposite directions, which is why the observation is worth having. Weak-sounding cosmetic language is not evidence that the evidence is weak — the phrasing is compelled by the category, so it carries almost no information about the underlying data. And strong-sounding cosmetic language should make you look harder, not relax — a cosmetic making an unhedged structure-function claim is either sitting on a drug-development program you have not heard of, or making a claim its category does not permit.

Either way, the category tells you nothing about whether the product works. That question is answered in Chapter 30, from the evidence, exactly as everywhere else.

⚠️ Not legal advice. DSHEA, the dietary-ingredient requirement, and the cosmetic structure-function boundary are United States rules as of this writing in 2026. Supplement and cosmetic regimes vary widely between jurisdictions — some far tighter, some far looser. Rules differ by jurisdiction and change.

G.9 Anti-doping

A different system entirely, with a different logic, binding a specific set of people. The World Anti-Doping Agency (WADA) publishes a Prohibited List, updated annually, adopted by national anti-doping organizations and international federations. Two categories cover most of this book.

BPC-157 was added to the Prohibited List under S0, effective from the 2022 List.

Why S0 breaks the argument most athletes make

Athletes reason about the Prohibited List as though it were an enumeration — a roster of named substances, and if yours is not on it, you are fine. That model is wrong, and S0 is why.

S0 is not a list of substances. It is a rule about a property. The property is "not approved by any governmental regulatory health authority for human therapeutic use," and it applies whether or not anyone at WADA has ever heard of the compound. A novel peptide synthesized last month and sold on a website is prohibited under S0 the moment it exists, because it satisfies the description.

Which gives the sharp point: "it isn't on the banned list" is usually wrong by construction. For a tested athlete, an unapproved experimental compound is prohibited precisely because it is unapproved. The very feature gray-market marketing presents as an advantage — outside the pharmaceutical system, unencumbered, not yet caught up in regulation — is what places it squarely inside S0. A second-order irony worth carrying: under S0's logic, a compound moving toward approval becomes less prohibited, not more.

The sanction does not depend on whether it works

An anti-doping violation is established by presence of a prohibited substance or its metabolites, or by use or attempted use, or by other defined violations. None of those definitions contains a clause about efficacy. An athlete who takes an unapproved compound that does absolutely nothing has committed the same violation as one who takes a compound that works.

Which is the chapter's thesis in its crispest form. BPC-157 is rated ❌ for its healing claims (Chapter 17) because the human literature is essentially empty, and it is prohibited under S0 because it is unapproved. Both are true. Neither caused the other. Neither would move if the other changed.

Who this binds

These rules bind athletes in tested sport — those subject to an anti-doping code through a federation, a national organization, an event, or an employer that has adopted one. Many readers of this book are not subject to them at all, and for those readers the Prohibited List is informational rather than binding. For those who are: the List changes annually, therapeutic use exemption processes exist with their own requirements and deadlines, and the rules are administered by organizations with their own procedures.

⚠️ Not legal advice, and not compliance advice. WADA's system is international but implemented through national organizations and federations whose procedures differ. Everything above is as of this writing in 2026, and the List is republished every year. If you are a tested athlete, check the current List and your own organization's resources — not this book, and not Chapter 38.

G.10 Glossary of regulatory terms

Alphabetical. Terms marked (US) are specific to United States practice; others are general or have close counterparts in many systems. All as of this writing in 2026, and all subject to §G.1.

503A (US) — Traditional pharmacy compounding for an identified individual patient on a patient-specific prescription. Exempt from certain requirements applying to manufactured drugs, including premarket approval. No premarket review of safety or efficacy (§G.7).

503B outsourcing facility (US) — A category created by federal legislation in 2013 for larger-scale compounders. Registers federally, may compound without patient-specific prescriptions, may distribute to healthcare facilities, and is subject to current good manufacturing practice requirements and federal inspection. Still no premarket review of safety or efficacy.

Accelerated approval — A pathway permitting approval on a surrogate endpoint reasonably likely to predict clinical benefit, with confirmatory trials required afterward. Confirmation is deferred, not waived (§G.4, Chapter 16).

Adverse event reporting — The mechanisms by which harms observed after a product reaches the market are collected and reviewed. What matters here is the absence: for gray-market compounds there is no reporting pathway, so "no reported side effects" describes silence rather than safety (Chapter 19).

BLA — Biologics License Application (US) — The application type for a biological product, including alpha-amino-acid polymers of more than 40 amino acids (§G.3).

Bioequivalence — The demonstration that a follow-on product delivers the same amount of the same active ingredient into the bloodstream on the same time course as the original — what a generic application rests on instead of repeating the clinical program.

Biological product (US) — A category including alpha-amino-acid polymers with a specific, defined sequence of more than 40 amino acids. Licensed through a BLA.

Biosimilar — A follow-on version of a biological product, approved through a pathway requiring extensive analytical and usually clinical comparability; substantially more demanding and expensive than a generic filing.

Black box warning — Informally, the most prominent warning a United States drug label can carry; formally a boxed warning, added when a regulator judges a risk serious enough to require highlighting.

Certificate of analysis (CoA) — A document reporting laboratory results for a sample. What it is not: a guarantee about the vial in your hand, and not a single test — identity, purity, content, sterility, and endotoxin are separate analyses, rarely all performed, and purity by chromatographic peak area is a different quantity from peptide content by mass (Chapter 34).

Compounding — Preparation of a medication for an individual patient by combining, mixing, or altering ingredients. Not manufacturing, and not subject to premarket approval (§G.7).

Dietary ingredient (US) — The statutory categories a substance must fall into to be lawfully sold as a dietary supplement. Regulators have taken the position that certain synthetic peptides do not qualify (§G.8).

Dietary supplement (US) — A category created by DSHEA with no premarket approval requirement. Membership requires that the substance qualify as a dietary ingredient.

Drug shortage list — An official listing of drugs in shortage. Listing can permit compounding of products otherwise restricted as essentially copies; when a shortage is declared resolved, that permission narrows (§G.7).

DSHEA (US) — The Dietary Supplement Health and Education Act of 1994, which established the United States dietary supplement category and its requirements.

Essentially a copy — A compounded product duplicating a commercially available approved drug. Generally restricted outside defined circumstances such as a shortage.

Generic — A follow-on version of an approved drug, approved through an abbreviated application resting on demonstrated bioequivalence rather than a repeated clinical program.

GMP — good manufacturing practice — Manufacturing quality requirements for regulated production. In the United States, 503B outsourcing facilities are subject to current GMP requirements and 503A compounding is not. A manufacturing standard, not a statement that a product works.

IND — Investigational New Drug application (US) — The filing that permits administration of an investigational compound to human beings. A permission to test, not an approval of anything.

Indication — The specific condition and population a drug is approved to treat. An approval without an indication is an incomplete statement (§G.2).

Interchangeability — An additional determination beyond biosimilarity, relevant to whether a biosimilar may be substituted at the pharmacy level without prescriber involvement.

Label — The reviewed document accompanying an approved drug, describing the approved use, the population studied, the dosing evaluated, the adverse events observed, and required warnings. It tells you what was submitted and approved, not what is known (§G.6).

Marketing authorization — The term used in the European Union and elsewhere for what United States practice calls an approval.

Monograph — A published standard for a substance or preparation, typically in a pharmacopeia, specifying identity, quality, purity, and the test methods used to establish them. The word also appears in other regulatory contexts with related but distinct meanings. A quality standard, not a finding that a substance is effective.

NDA — New Drug Application (US) — The application type for a drug, including peptides of 40 or fewer amino acids (§G.3).

Off-label prescribing — A licensed prescriber's use of an approved drug for an unapproved indication. Lawful in the United States and many other jurisdictions. Says nothing about the state of the evidence (§G.6).

Off-label promotion — A manufacturer's marketing of a drug for an unapproved use. Generally prohibited; the asymmetry with prescribing is deliberate.

Orphan designation — A status a regulator may grant to a product intended for a rare disease, carrying development incentives. Criteria, incentives, and the definition of "rare" differ between jurisdictions. A designation is not an approval.

Pharmacopeia — An official compendium of quality standards for medicinal substances and preparations, organized as monographs. Several exist; which applies depends on jurisdiction and context.

Pharmacovigilance — The ongoing activity of detecting, assessing, understanding, and acting on adverse effects of medicines after they reach the market — the systematic form of §G.2's point that an approval is not a statement that all long-term effects are known.

Post-marketing surveillance (Phase 4) — Study and monitoring after approval, including any confirmatory trials required as a condition of it. It exists because Phase 3 trials are not large or long enough to characterize rare or long-latency effects. Never truly finished.

Prohibited List — WADA's annually updated list of prohibited substances and methods, adopted by anti-doping organizations and sporting federations. Because it is republished every year, an undated reference to it goes stale without telling you (§G.9).

Recall — The removal or correction of a product already on the market; like withdrawal and label revision, one of the mechanisms by which an approval turns out not to be permanent.

REMS — Risk Evaluation and Mitigation Strategy (US) — A mechanism by which a regulator may require a safety program as a condition of approval or continued marketing, going beyond what the label alone accomplishes. A reminder that "approved" is not a single uniform status.

Research use only — A seller's disclaimer stating a product is not for human consumption. A liability posture, not a regulatory category conferred by any agency (§G.8).

S0 — Non-Approved Substances — The WADA category prohibiting, at all times, any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. A rule about a property, not a list of names (§G.9).

S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics — The WADA category covering growth hormone and its releasing factors, IGF-1 and analogs, agents affecting erythropoiesis, and related compounds and mimetics.

Surrogate endpoint — A measured quantity used as a stand-in for the outcome that actually matters to patients. Chapter 16 is about why the substitution can fail; §G.4 is about why regulation deliberately relies on it anyway.

Therapeutic use exemption — A process by which an athlete may be permitted to use an otherwise prohibited substance for a documented medical need, subject to the relevant organization's requirements and deadlines.

⚠️ Not legal advice. These definitions help you read a claim; they do not establish what any rule requires of you. Terms marked (US) are United States practice as of this writing in 2026, and several have counterparts elsewhere that are similar in purpose and different in detail. Rules differ by jurisdiction and change.

G.11 International: how to think about it

There is no country-by-country table in this appendix, and its absence is the content. Such a table would be wrong within a year and would tempt you to use it as a substitute for looking. What follows is the durable thing instead: a way of interpreting the sentence "it's approved in [country]."

Different agencies — the FDA in the United States, the EMA for the European Union, the MHRA in the United Kingdom, the PMDA in Japan, the TGA in Australia, and national authorities elsewhere — apply broadly similar principles. They all ask whether the evidence shows benefits outweighing risks for a defined use, they read each other's assessments, and they often converge. And they routinely reach different conclusions, for at least four reasons that carry very different weight.

"Approved in [country]" is a fact worth knowing and a poor substitute for looking at the evidence the approval rested on.

It is worth knowing, because it tells you that somebody's regulator saw a dossier and said yes — more than an empty file, and a reader who waves it away has made the cynic's version of the error. But it does not tell you how large the dossier was, what standard it was judged against, whether the endpoint was clinical or surrogate, or whether the approval is decades old and rests on evidence nobody would accept for a new filing today. Take the regulatory fact as a pointer, then go read what it points at.

Three questions get you further than any table would. Which jurisdiction, and what is that system's standard for this kind of product? Approved for what indication, in what population — the same question as §G.2, since a foreign approval carries the identical qualifiers? And what was the underlying assessment — which trials, what design, what endpoint? A foreign approval resting on adequate randomized trials with clinical endpoints is strong evidence because of the trials, not because of the approval.

⚠️ Not legal advice, and deliberately not a guide to any non-US system. The agencies above are named as examples of the structure, not described. As of this writing in 2026. Nothing in this section addresses import, export, possession, or what any reader may lawfully obtain anywhere — those rules differ enormously, this book does not advise on them, and the question belongs with someone qualified in your own jurisdiction.

G.12 The one thing to carry

Everything in this appendix is perishable. The forty-amino-acid line could be redrawn. The compounding rules already moved once inside the period this book covers. The Prohibited List is republished every year, by design. If you are reading this in a later decade, treat every specific above as a question rather than an answer.

One thing is not perishable, and it is the reason the appendix exists:

Regulatory status tells you what has been submitted and judged. Evidence tells you what is known. They correlate. They are not the same thing.

They correlate because a well-supported compound with a commercial sponsor usually does get filed and usually does get approved, and because a filed application is scrutinized more intensely than almost any published paper. Approval is genuine information. They diverge because filing is a business decision; because agencies differ; because whole categories — supplement, cosmetic ingredient, research reagent — route products around the drug system entirely; and because clinical evidence gets funded on the basis of ownership rather than of what would be useful to know.

Both errors treat a regulatory file as though it were a body of evidence. They are made by people who despise each other, from opposite directions, and they are the same error.

So when you meet a regulatory fact anywhere — on a label, on a vendor page, in a headline, in this appendix — do what Chapter 5 trained you to do. Ask which of §G.5's five cases applies. Ask what jurisdiction and what date. Ask what indication and what population. Then go and read the evidence, because Chapter 5's method is the one you apply — not the label.

And once more, because it is the sentence that protects you best: nothing here is legal advice, the rules described differ by country and change, and no passage in this appendix tells you what you may lawfully do. For that, ask the current rules of your own jurisdiction, and someone qualified to read them.

Related: Chapter 5 (the method) · Chapter 10 (attrition and base rates) · Chapter 12 (access and cost) · Chapter 16 (surrogate endpoints) · Chapter 17 (BPC-157) · Chapter 19 (the gray market) · Chapter 28 (nesiritide) · Chapter 30 (cosmetic peptides) · Chapter 34 (what analysis establishes) · Chapter 36 (the economics of development) · Chapter 38 (the argument this appendix condenses) · Chapter 39 (talking to a clinician) · Appendix C (the dossier, Field 10) · Appendix D (reading a trial) · Appendix F (red flags)